XOMA Corporation (XOMAP) Financials
XOMAP Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 271.9 million | 159.0 million |
| Dec. 31, 2025 | 272.7 million | 168.7 million |
| Sept. 30, 2025 | 263.2 million | 155.2 million |
| June 30, 2025 | 223.5 million | 131.0 million |
XOMAP Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | 6.0 million | 2.3 million |
| Dec. 31, 2025 | -5.5 million | 3.9 million |
| Sept. 30, 2025 | -296000 | 1.8 million |
| June 30, 2025 | 6.4 million | 1.6 million |
XOMAP Net Income
No data available :(
XOMAP Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 95.0 million | 88.8 million | 19.5 million |
| Dec. 31, 2025 | 82.9 million | 96.5 million | 20.1 million |
| Sept. 30, 2025 | 92.0 million | 94.4 million | 20.7 million |
| June 30, 2025 | 83.9 million | 102.2 million | 710000 |
XOMAP Shares Outstanding
XOMAP Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | - | 49000 | 11.9 million | - |
| Dec. 31, 2025 | - | 281000 | 10.4 million | - |
| Sept. 30, 2025 | 111000 | 69000 | 9.7 million | - |
| June 30, 2025 | - | 69000 | 7.8 million | - |
XOMAP Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | 12.3 million | 895000 |
| Dec. 31, 2025 | 1.4 million | 135000 |
| Sept. 30, 2025 | 532000 | 878000 |
| June 30, 2025 | 13.1 million | 655000 |
XOMAP
Price: $25.51
Dividend Yield: 8.47%
Forward Dividend Yield: 8.45%
Payout Ratio: 215.41%
Dividend Per Share: 2.16 USD
Earnings Per Share: 1.00 USD
P/E Ratio: 25.27
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 1300
Market Capitalization: 307.1 million
Average Dividend Frequency: 4
Years Paying Dividends: 6